Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Trial of RP1 + Nivolumab in Anti-PD1 Failed Melanoma Announced June 11, 2024
FAILED TRIAL: Confirmatory Ph 3 TROPiCS-04 study in locally advanced/metastatic urothelial cancer (mUC) did not meet the primary endpoint of OS in the ITT population June 4, 2024
Positive Initial Interim Safety and Efficacy Results Announced from RAMP 205 Trial of Avutometinib, Defactinib, Gemcitabine and Nab-paclitaxel combo in 1L Metastatic Pancreatic Cancer May 29, 2024
FAILED TRIAL: Datopotamab deruxtecan showed clinically meaningful OS improvement vs. chemo in patients with advanced nonsquamous NSCLC in TROPION-Lung01 Ph 3 trial May 29, 2024
Ph 2/3 Trial of Surufatinib + Camrelizumab combo for 1L Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui Initiated May 21, 2024
Updated Clinical Data from Ph 1b Trial of Vepdegestrant + Palbociclib (IBRANCE) Announced May 21, 2024
VERSATILE-002 Ph 2 Trial Meets Primary Study Endpoints in 1l Recurrent/Metastatic HPV16-Positive Head and Neck Cancer May 15, 2024
FAILED TRIAL: Ph 3 KEYNOTE-B21 trial of adjuvant KEYTRUDA + chemo +/- RT did not meet primary endpoint of DFS in newly diagnosed, high-risk endometrial cancer after surgery with curative intent May 15, 2024
Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201 May 15, 2024
Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced May 15, 2024
Higher AML Complete Remission (CR) Rates and Significant Durability Reported with Additional Interim Subject Data May 15, 2024
Initial Data from Investigator-Initiated Ph 2 Trial of ZYNLONTA® in Patients with R/R MZL Announced May 14, 2024
FAILED TRIAL: Ph 3 CheckMate -73L trial did not meet primary endpoint of PFS in unresectable, locally advanced stage III NSCLC May 14, 2024
FAILED TRIAL: Pivotal Ph 3 Study of Uproleselan in R/R AML patients did not meet primary endpoint of OS in the intent-to-treat population May 14, 2024
Ph 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as 1L Treatment in Patients With HER2+ve Advanced Gastric/GEJ Adenocarcinoma May 7, 2024
Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Ph 2 Trial in Advanced Ovarian Cancer May 7, 2024
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer May 7, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC May 7, 2024
